Education
About Us
Working with TipRanks
Follow Us
Nuvalent (NUVL)
NASDAQ:NUVL
NUVL Stock Chart & Stats
$102.63
-$0.36(-0.45%)
At close: 4:00 PM EST
$102.63
-$0.36(-0.45%)
Day’s Range― - ―
52-Week Range$55.54 - $112.88
Previous CloseN/A
Volume65.93K
Average Volume (3M)656.54K
Market Cap
$7.46B
Enterprise Value$5.30B
Total Cash (Recent Filing)$943.10M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.03
Next Earnings
Mar 04, 2026EPS Estimate
-1.48Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.70
Shares Outstanding67,271,460
10 Day Avg. Volume527,644
30 Day Avg. Volume656,543
Financial Highlights & Ratios
PEG Ratio-0.25
Price to Book (P/B)4.86
Price to Sales (P/S)0.00
P/FCF Ratio-28.09
Enterprise Value/Market Cap0.71
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-12.98
Forecast
1Y Price Target
$141.00Price Target Upside37.39% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering16
EPS Forecast (FY)-5.71
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessNuvalent reported positive topline data from the ongoing ALKOVE-1 study which paves the way for neladalkib to be filed as a 2L therapy for ALK-positive NSCLC patients.
Commercial PotentialThe company is well-positioned to become a commercial entity by the end of 2026, with expectations for zildesamtinib to receive accelerated approval as a therapy for ROS1-positive NSCLC.
Efficacy And SafetyNeladalkib showed good intracranial activity in the 2L patient cohort with an IC-ORR of 63% and an IC-CR of 21%.
Bears Say
Nuvalent News
NUVL FAQ
What was Nuvalent’s price range in the past 12 months?
Nuvalent lowest stock price was $55.53 and its highest was $112.88 in the past 12 months.
What is Nuvalent’s market cap?
Nuvalent’s market cap is $7.46B.
When is Nuvalent’s upcoming earnings report date?
Nuvalent’s upcoming earnings report date is Mar 04, 2026 which is in 75 days.
How were Nuvalent’s earnings last quarter?
Nuvalent released its earnings results on Oct 30, 2025. The company reported -$1.7 earnings per share for the quarter, missing the consensus estimate of -$1.569 by -$0.131.
Is Nuvalent overvalued?
According to Wall Street analysts Nuvalent’s price is currently Undervalued.
Does Nuvalent pay dividends?
Nuvalent does not currently pay dividends.
What is Nuvalent’s EPS estimate?
Nuvalent’s EPS estimate is -1.48.
How many shares outstanding does Nuvalent have?
Nuvalent has 67,271,460 shares outstanding.
What happened to Nuvalent’s price movement after its last earnings report?
Nuvalent reported an EPS of -$1.7 in its last earnings report, missing expectations of -$1.569. Following the earnings report the stock price went down -4.662%.
Which hedge fund is a major shareholder of Nuvalent?
Currently, no hedge funds are holding shares in NUVL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Nuvalent Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$141.00 (37.39% Upside)
$141.00 (37.39% Upside)
Blogger Sentiment
Bullish
NUVL Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.5M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $70.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 23.2%
Last 30 Days ▲ 23.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
17.39%
12-Months-Change
Fundamentals
Return on Equity
-38.79%
Trailing 12-Months
Asset Growth
-17.58%
Trailing 12-Months
Company Description
Nuvalent
Nuvalent, Inc. is an innovative biotechnology company focused on creating small molecule medicines for patients with cancer. The company specializes in developing precision-targeted therapies for clinically proven kinase targets in cancer treatment. Nuvalent's core products are designed to address the limitations of existing therapies, with a focus on resistance, selectivity, and brain penetration to provide significant improvements for patients.
NUVL Stock 12 Month Forecast
Average Price Target
$141.00
▲(37.39% Upside)
Technical Analysis
Ownership Overview
Currently, No data available
---